Andrew J. Fromkin - Apr 2, 2024 Form 4 Insider Report for Immunovant, Inc. (IMVT)

Role
Director
Signature
/s/ Eva Renee Barnett, attorney-in-fact for Andrew J. Fromkin
Stock symbol
IMVT
Transactions as of
Apr 2, 2024
Transactions value $
$0
Form type
4
Date filed
4/4/2024, 04:54 PM
Previous filing
Dec 5, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IMVT Common Stock Award $0 +11.3K +12.69% $0.00 99.9K Apr 2, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMVT Stock Option (right to buy) Award $0 +4.69K $0.00 4.69K Apr 2, 2024 Common Stock 4.69K $30.78 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 2, 2025, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A.
F2 The shares underlying the options will vest on April 2, 2025, subject to the Reporting Person's continuous service to the Issuer as of such date.